Clinician-to-Clinician Update Clinician-to-Clinician Update

Heart Care Specialty Updates

November 2016

Nov-2016-Heart-Care-Spec-UpdateThenappan Thenappan 1508842048 MH Bio
— Thenappan Thenappan, MD

Clinical trial to study use of a beta blocker for PAH

University of Minnesota Health announces an enrolling clinical trial to test the safety and tolerability of longer-term use of carvedilol in treating pulmonary arterial hypertension (PAH). Led by principal investigator Thenappan Thenappan, MD, the phase II pilot study is to run 12 months. Investigators are currently recruiting adult patients with PAH who have right heart failure, with right ventricular ejection fractions less than 45% and a mean pulmonary artery pressure greater than 25 mmHg. University of Minnesota Health cardiologist Marc Pritzker, MD, serves as co-investigators on the trial. Beta-blockers are not currently used to treat PAH, although animal studies suggest that they may be effective in treating patients with PAH. If found beneficial in clinical trials, carvedilol will become the first beta-blocker used specifically to treat patients with PAH. Funding for the trial was obtained from the Lillehei Heart Institute, the American Heart Association, and an anonymous donor.

M Health recognized as Pulmonary Hypertension Care Center

University of Minnesota Health has earned recognition as a Pulmonary Hypertension Care Center, a certification granted by the Pulmonary Hypertension Association. The designation is reserved for healthcare facilities that demonstrate the highest level of care in the diagnosis and management of all classes of pulmonary hypertension. The M Health program is one of only 36 in the country to achieve certification. Led by University of Minnesota Health cardiologist Marc Pritzker, MD, the pulmonary hypertension care group includes cardiologists, nurses, and care coordinators who specialize in treating the condition. The team is now actively treating nearly 1,000 patients with pulmonary hypertension.

For information on the designation, visit

Related Articles

November 2016

Treating Pulmonary Hypertension

New drug therapies and surgical interventions are extending the life expectancy of patients with pulmonary hypertension, a condition that, while rare, complicates the course of many diseases.

Continue reading

November 2016

Skilled Reevaluation Spares Patient with PAH from Heart-Lung Transplant

A patient with pulmonary hypertension and exercise intolerance is referred for surgery. A full reevaluation and new drug therapy stabilize the patient’s condition and return her to her former activities.

Continue reading